RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Karuna Therapeutics - Stock

Karuna Therapeutics Stocks 2024

Karuna Therapeutics Stocks

36.96 M

Karuna Therapeutics Dividend yield

Ticker

KRTX

ISIN

US48576A1007

WKN

A2PM5N

In 2024, Karuna Therapeutics had 36.96 M outstanding stocks, a 0% change from the 36.96 M stocks in the previous year.

The Karuna Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e36.96
2028e36.96
2027e36.96
2026e36.96
2025e36.96
2024e36.96
202336.96
202231.63
202129.14
202026.45
201926.01
201821.37
201721.37

Karuna Therapeutics Aktienanalyse

What does Karuna Therapeutics do?

Karuna Therapeutics Inc. is an American biotechnology company based in Boston, Massachusetts. It was founded in 2009 by Dr. Andrew Miller and Dr. Stephen Murray and specializes in the research and development of novel treatment methods for mental disorders. The history of Karuna Therapeutics begins with the recognition by the founders that there were not enough effective medications for mental disorders. They saw a great opportunity to fill this gap and help patients through their research and development of innovative therapies. The business model of Karuna Therapeutics is to develop novel medications for mental disorders that can complement or replace existing treatment methods. The company utilizes the latest scientific advancements to better understand the role of the brain and neurotransmitters in various disorders. Karuna Therapeutics specializes in the development of treatments for severe mental disorders such as schizophrenia, dementia, depression, and anxiety disorders. These disorders have a significant impact on the affected individuals, their families, and society as a whole. Patients with these disorders urgently need more effective treatment options to lead a normal life. The main focus of Karuna Therapeutics is the research and development of new therapies for mental disorders. The company collaborates closely with some of the most renowned scientists and researchers in this field to develop innovative approaches to treating central nervous system disorders. Currently, Karuna Therapeutics is developing a medication called "KarXT" for the treatment of schizophrenia and akathisia. KarXT is based on the combination of two known active substances that complement each other in a specific way to achieve improved efficacy. The medication is currently undergoing Phase III studies to assess its effectiveness and safety. Another product of Karuna Therapeutics is "KarGABA," an oral medication being developed for the treatment of anxiety disorders. The medication is based on a neurotransmitter responsible for relaxation and calming of the body. KarGABA is still in the early stages of development. Overall, Karuna Therapeutics invests a significant portion of its budget in research and development of new therapies. The company focuses on breaking down the traditional boundaries between different types of mental disorders and finding new ways to treat them. In summary, Karuna Therapeutics is an ambitious company dedicated to the research and development of new innovative treatment methods for mental disorders. The company aims to help affected patients and improve the lives of millions of people worldwide. Karuna Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Karuna Therapeutics's Shares Outstanding

Karuna Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Karuna Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Karuna Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Karuna Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Karuna Therapeutics Stock

How many stocks are there of Karuna Therapeutics?

The current number of stocks of Karuna Therapeutics is 36.96 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Karuna Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Karuna Therapeutics evolved in recent years?

The number of shares of Karuna Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Karuna Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Karuna Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Karuna Therapeutics pay?

Over the past 12 months, Karuna Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Karuna Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Karuna Therapeutics?

The current dividend yield of Karuna Therapeutics is .

When does Karuna Therapeutics pay dividends?

Karuna Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Karuna Therapeutics?

Karuna Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Karuna Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Karuna Therapeutics located?

Karuna Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Karuna Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Karuna Therapeutics from 6/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/11/2024.

When did Karuna Therapeutics pay the last dividend?

The last dividend was paid out on 6/11/2024.

What was the dividend of Karuna Therapeutics in the year 2023?

In the year 2023, Karuna Therapeutics distributed 0 USD as dividends.

In which currency does Karuna Therapeutics pay out the dividend?

The dividends of Karuna Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Karuna Therapeutics

Our stock analysis for Karuna Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karuna Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.